- Home
- IDAI vs ALZN Comparison
IDAI vs ALZN Comparison
Compare IDAI & ALZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDAI
- ALZN
- Stock Information
- Founded
- IDAI 2016
- ALZN 2016
- Country
- IDAI United States
- ALZN United States
- Employees
- IDAI N/A
- ALZN N/A
- Industry
- IDAI Computer Software: Prepackaged Software
- ALZN Medicinal Chemicals and Botanical Products
- Sector
- IDAI Technology
- ALZN Health Care
- Exchange
- IDAI Nasdaq
- ALZN Nasdaq
- Market Cap
- IDAI 5.5M
- ALZN 4.5M
- IPO Year
- IDAI N/A
- ALZN 2021
- Fundamental
- Price
- IDAI $2.34
- ALZN $0.56
- Analyst Decision
- IDAI
- ALZN Strong Buy
- Analyst Count
- IDAI 0
- ALZN 1
- Target Price
- IDAI N/A
- ALZN $20.00
- AVG Volume (30 Days)
- IDAI 54.1K
- ALZN 169.0K
- Earning Date
- IDAI 05-20-2025
- ALZN 03-10-2025
- Dividend Yield
- IDAI N/A
- ALZN N/A
- EPS Growth
- IDAI N/A
- ALZN N/A
- EPS
- IDAI N/A
- ALZN N/A
- Revenue
- IDAI $3,082,348.00
- ALZN N/A
- Revenue This Year
- IDAI $65.46
- ALZN $322.64
- Revenue Next Year
- IDAI $12.00
- ALZN N/A
- P/E Ratio
- IDAI N/A
- ALZN N/A
- Revenue Growth
- IDAI N/A
- ALZN N/A
- 52 Week Low
- IDAI $0.15
- ALZN $0.63
- 52 Week High
- IDAI $8.96
- ALZN $15.06
- Technical
- Relative Strength Index (RSI)
- IDAI 64.74
- ALZN 23.57
- Support Level
- IDAI $1.94
- ALZN $0.51
- Resistance Level
- IDAI $2.13
- ALZN $0.72
- Average True Range (ATR)
- IDAI 0.16
- ALZN 0.05
- MACD
- IDAI 0.06
- ALZN -0.01
- Stochastic Oscillator
- IDAI 91.07
- ALZN 10.00
About IDAI T Stamp Inc.
T Stamp Inc develops and markets identity authentication software solutions for enterprise partners and peer-to-peer markets. The company is engaged in developing proprietary artificial intelligence-powered solutions; researching and leveraging biometric science, cryptography, and data mining to deliver insightful identity & trust predictions while identifying and defending against fraudulent identity attacks, protecting sensitive user information, and extending the reach of digital services through accessibility.
About ALZN Alzamend Neuro Inc.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.